Search Results Showing 5 of 5 search results for: Study of bb2121 in Multiple Myeloma Status Active, not recruiting Condition Multiple Myeloma Phase Phase 1 INTERVENTION Biological: bb2121 Eligibility Ages Eligible for Study : Sexes Eligible for Study : All Accepts Healthy Volunteers : Result 1 of 5 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Status Recruiting Condition Multiple Myeloma Phase Phase 3 INTERVENTION Biological: bb2121, Drug: Daratumumab, Drug: Pomalidomide, Drug: Dexamethasone, Drug: Bortezomib, Drug: Ixazomib, Drug: Lenalidomide, Drug: Carfilzomib, Drug: Elotuzumab Eligibility Ages Eligible for Study : Sexes Eligible for Study : All Accepts Healthy Volunteers : Result 2 of 5 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) Status Recruiting Condition Multiple Myeloma Phase Phase 1 INTERVENTION Biological: bb2121 carfilzomib, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Lenalidomide Eligibility Ages Eligible for Study : Sexes Eligible for Study : All Accepts Healthy Volunteers : Result 3 of 5 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma Status Active, not recruiting Condition Multiple Myeloma Phase Phase 2 INTERVENTION Biological: bb2121 Eligibility Ages Eligible for Study : Sexes Eligible for Study : All Accepts Healthy Volunteers : Result 4 of 5 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Status Recruiting Condition Multiple Myeloma Phase Phase 2 INTERVENTION Biological: bb2121 Eligibility Ages Eligible for Study : Sexes Eligible for Study : All Accepts Healthy Volunteers : Result 5 of 5